Loading content
Professor Martin Hoyle

Professor Martin Hoyle

Associate Professor in Health Economics

6076

South Cloisters 

Prof Martin Hoyle is a health economist, lead modeller, and, since May 2015, Director of PenTAG (Peninsula Technology Assessment Group).  He performs heath technology assessments mainly for NICE, but also for the NIHR.  

Prof Hoyle has evaluated drugs in several clinical areas including various cancers (chronic lymphocytic leukaemia, chronic myeloid leukaemia, multiple myeloma, neuroendocrine tumours, colorectal cancer, gastro-intestinal stromal tumours, renal cell carcinoma, soft tissue sarcoma), chemotherapy-induced anaemia, multiple sclerosis, Alzheimer's disease. Other evaluations include cochlear implants for hearing, diagnostic tests for Lynch Syndrome and tests for pre-term labour in women. He has defended PenTAG reports at about 30 NICE Appraisal Committee meetings.

His undergraduate training was in Mathematics at the University of Cambridge.  This accounts for his interest in the mathematics and statistics of HTA.  He has published papers on HTA methodology, specifically on assumptions regarding appropriate patient cohorts to model, assumptions for future drug prices and a method to recreate and analyse individual patient data using only summary survival data.

He is the external examiner for the MSc in Health Economics and Decision Modelling, University of Sheffield, a panel member for the Research for Patient Benefit (RfPB) South West.  He is also an advisor to NICE on implementation of the NICE Fast Track Appraisal (FTA) process and an advisor to NICE on implementation of the "Adjusted TA" process.

Outside work, most of his time is spent looking after his three children.  What little time is left is spent learning the piano, listening to the radio, or on holiday in Corsica or the Canary Islands.

 

 

Qualifications

  • 2004 PhD Mathematical biology (University of Nottingham)
  • 2000 MSc Ecology (University of Bangor),
  • 1993 Diploma Statistics (University of Cambridge),
  • 1992 MA Mathematics (University of Cambridge)

Research

Research interests

  • Economic analysis of health technologies, especially cancers
  • Economic analysis of diagnostic tests
  • Future drug price assumptions in HTA
  • Prevalent and multiple incident cohorts in HTA
  • Survival analysis in HTA
  • NICE HTA process

Research projects

  • Everolimus, lutetium and sunitinib for treating neuroendocrine tumours, report to NICE December 2016.
  • Cetuximab and panitumumab for 1st-line metastatic colorectal cancer, report to NICE August 2015.
  • Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA 142), Report submitted to NICE Jan 2014.
  • A systematic review and economic evaluation of diagnostic strategies for Lynch Syndrome, commissioned by NIHR. Report submitted to NIHR June 2013.

Grants/Funding

Prof Hoyle helped to regain the Technology Assessment Review contract with Dept. for Health for work for NICE and NIHR for the period 2016 to 2021. The total value of the grant is �3.6 million. His contribution equates to 40%, or �288,000 per year.

Dr Hoyle is credited with a contribution of 15% in gaining the Technology Assessment Review contract with Dept. for Health for work for NICE and NIHR for the period 2011 to 2016. The total value of the grant is �3.5 million. His contribution equates to �105,000 per year.

Research grants

  • 2014 Department of Health
    Technology Assessments for NIHR and NICE
  • 2014 RCUK Newton Fund
    Brazil-UK collaboration in Health Technology Assessment of diagnostic strategies for infectious diseases

Links


Key publications | Publications by category | Publications by year

Key publications


Hoyle M (2011). Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis. Pharmacoeconomics, 29(1), 1-15. Abstract.  Author URL.
Hoyle MW, Henley W (2011). Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol, 11. For Spreadsheet to implement method, click on Author URL Abstract.  Author URL.  Full text.
Hoyle MW, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Hyde C (2011). The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model. Submitted to NICE as MTA report.  Author URL.
Hoyle M, Anderson R (2010). Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts. Med Decis Making, 30(4), 426-437. Abstract.  Author URL.  Full text.
Hoyle M (2008). Future drug prices and cost-effectiveness analyses. Pharmacoeconomics, 26(7), 589-602. Abstract.  Author URL.

Publications by category


Journal articles

Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long H, Medina-Lara A, et al (In Press). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model. Health Technology Assessment Abstract.  Full text.
Tikhonova IA, Hoyle MW, Snowsill TM, Cooper C, Varley-Campbell JL, Rudin CE, Mujica Mota RE (2017). Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: an Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. Pharmacoeconomics, 35(3), 363-373. Abstract.  Author URL.
Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, et al (2016). Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess, 20(62), 1-594. Abstract.  Author URL.  Full text.
Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C (2015). A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC Cancer, 15 Abstract.  Author URL.  Full text.
Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C (2014). A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technology Assessment, 18(58). Author URL.  Full text.
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long L, Medina-Lara A, et al (2014). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model.  Author URL.
Ciani O, Hoyle M, Pavey T, Cooper C, Garside R, Rudin C, Taylor R (2013). Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case-study for technology appraisal on the basis of surrogate outcomes evidence. Value in Health, 6(16), 1081-1090.
Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C (2013). Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer. Value Health, 16(2), 288-296. Abstract.  Author URL.
Peters JL, Anderson R, Hoyle M, Hyde C (2013). Evolution of a cost-utility model of donepezil for Alzheimer's disease. Int J Technol Assess Health Care, 29(2), 147-154. Abstract.  Author URL.
Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P, Moxham T, et al (2013). Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. Age Ageing, 42(1), 14-20. Abstract.  Author URL.
Joulain F, Proskorovsky I, Allegra C, Tabernero J, Hoyle M, Iqbal SU, Van Cutsem E (2013). Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. British Journal of Cancer, 109(7), 1735-1743. Author URL.
Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Tappenden P, Hyde C (2013). The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol Assess, 17(14), 1-237. Abstract.  Author URL.  Full text.
Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K (2012). Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess, 16(22), 1-410. Abstract.  Author URL.  Full text.
Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, et al (2012). Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: Systematic reviews and economic analyses. Health Technology Assessment, 16, 1-278. Abstract.  Author URL.
Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, et al (2012). The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess, 16(21), 1-470. Abstract.  Author URL.  Full text.
Hoyle M (2011). Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis. Pharmacoeconomics, 29(1), 1-15. Abstract.  Author URL.
Hoyle M, Rogers G, Moxham T, Liu Z, Stein K (2011). Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health, 14(8), 1057-1067. Abstract.  Author URL.
Hoyle MW (2011). GENERAL METHODOLOGICAL ISSUES IN COST-EFFECTIVENESS ANALYSIS INSPIRED BY THE ASSESSMENT OF DASATINIB, NILOTINIB AND IMATINIB FOR CHRONIC MYELOID LEUKAEMIA. VALUE IN HEALTH, 14(7), A425-A425. Author URL.
Hoyle MW, Henley W (2011). Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol, 11. For Spreadsheet to implement method, click on Author URL Abstract.  Author URL.  Full text.
Hoyle M, Crathorne L, Garside R, Hyde C (2011). Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Health Technol Assess, 15 Suppl 1, 61-67. Abstract.  Author URL.
Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K (2010). Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess, 14(2), 1-iv. Abstract.  Author URL.  Full text.
Hoyle M, Green C, Thompson-Coon J, Liu Z, Welch K, Moxham T, Stein K (2010). Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. Value Health, 13(1), 55-60. Abstract.  Author URL.
Hoyle M, Green C, Thompson-Coon J, Liu Z, Welch K, Moxham T, Stein K (2010). Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma. Value Health, 13(1), 61-68. Abstract.  Author URL.
Hoyle M (2010). Historical lifetimes of drugs in England: application to value of information and cost-effectiveness analyses. Value Health, 13(8), 885-892. Abstract.  Author URL.
Hoyle MW (2010). IMPROVED SURVIVAL CURVE FITS TO SUMMARY DATA FOR ECONOMIC EVALUATIONS. VALUE IN HEALTH, 13(7), A339-A339. Author URL.
Hoyle M, Anderson R (2010). Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts. Med Decis Making, 30(4), 426-437. Abstract.  Author URL.  Full text.
Hoyle M (2009). ACCOUNTING FOR THE DRUG LIFE CYCLE AND FUTURE DRUG PRICES IN COST EFFECTIVENESS ANALYSIS. VALUE IN HEALTH, 12(7), A233-A233. Author URL.
Hoyle M, Cresswell JE (2009). Maximum feasible distance of windborne cross-pollination in Brassica napus: a 'mass budget' model. Ecological Modelling, 220(8), 1090-1097. Abstract.
Thompson Coon JS, Liu Z, Hoyle M, Rogers G, Green C, Moxham T, Welch K, Stein K (2009). Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer, 101(2), 238-243. Abstract.  Author URL.  Full text.
Bond M, Hoyle M, Moxham T, Napier M, Anderson R (2009). Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer. Health Technol Assess, 13 Suppl 2, 69-74. Abstract.  Author URL.
Bond M, Mealing S, Anderson R, Elston J, Weiner G, Taylor RS, Hoyle M, Liu Z, Price A, Stein K, et al (2009). The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. Health Technol Assess, 13(44), 1-330. Abstract.  Author URL.  Full text.
Bond M, Pitt M, Akoh J, Moxham T, Hoyle M, Anderson R (2009). The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model. Health Technology Assessment, 13(38), xi-180. Author URL.
Hoyle M (2008). Future drug prices and cost-effectiveness analyses. Pharmacoeconomics, 26(7), 589-602. Abstract.  Author URL.
Hoyle M, Cresswell JE (2007). A search theory model of patch-to-patch forager movement with application to pollinator-mediated gene flow. J Theor Biol, 248(1), 154-163. Abstract.  Author URL.
Hoyle M, Hayter K, Cresswell JE (2007). Effect of pollinator abundance on self-fertilization and gene flow: application to GM Canola. Ecol Appl, 17(7), 2123-2135. Abstract.  Author URL.
Cresswell JE, Hoyle M (2007). The effect of wind direction on cross-pollination in wind-pollinated GM crops. Ecological Applications, 17(4), 1234-1243.
Hoyle M (2007). When corridors work: Insights from a microecosystem. ECOLOGICAL MODELLING, 202(3-4), 441-453. Author URL.
Cresswell JE, Hoyle, M. (2006). A mathematical method for estimating patterns of flower-to-flower gene dispersal from a simple field experiment. Functional Ecology, 20, 245-251.
Cresswell, J.E. (2006). Remobilization of initially deposited pollen grains has negligible impact on gene dispersal in bumble bee-pollinated Brassica napus. Functional Ecology, 20, 958-965.
Hoyle M (2005). Experimentally fragmented communities are more aggregated. Journal of Animal Ecology, 74(3), 430-442. Abstract.
Hoyle M, James M (2005). Global warming, human population pressure, and viability of the world's smallest butterfly. Conservation Biology, 19(4), 1113-1124. Abstract.
Hoyle M, Harborne AR (2005). Mixed effects of habitat fragmentation on species richness and community structure in a microarthropod microecosystem. Ecological Entomology, 30(6), 684-691. Abstract.
Hoyle M (2004). Causes of the species-area relationship by trophic level in a field-based microecosystem. Proc Biol Sci, 271(1544), 1159-1164. Abstract.  Author URL.
Jackson J, Turner J, Rentoul L, Faulkner H, Behnke J, Hoyle M, Grencis R, Else K, Kamgno J, Bradley J, et al (2004). Cytokine response profiles predict species-specific infection patterns in human GI nematodes. International Journal for Parasitology, 34, 1237-1244.
Hoyle MW, Gilbert F (2004). Species richness of moss landscapes unaffected by short-term fragmentation. Oikos, 105, 359-367.
Jackson J, Turner J, Rentoul L, Faulkner H, Behnke J, Hoyle M, Grencis R, Else K, Kamgno J, Boussinesq M, et al (2004). T Helper Cell Type 2 responsiveness predicts future susceptibility to gastrointestinal nematodes in humans. Journal of Infectious Diseases, 190, 1804-1811.

Conferences

Tikhonova IA, Hoyle M, Snowsill T, Cooper C, Varley-Campbell J, Rudin C, Mujica Mota R (2016). Azacitidine for Treating Acute Myeloid Leukaemia: a Nice Single Technology Appraisal. ISPOR.
Tikhonova IA, Hoyle M, Snowsill T, Crathorne L, Varley-Campbell J, Peters J, Briscoe S, Bond M, Huxley N (2016). Cost Effectiveness of Cetuximab and Panitumumab for First-Line RAS WT Metastatic Colorecal Cancer. ISPOR.
Haasova M, Jones-Hughes T, Peters J, Snowsill T, Coelho H, Crathorne L, Mujica Mota R, Varley-Campbell J, Huxley N, Moore J, et al (2016). Immunosuppressive therapy for renal transplantation in adults: a systematic review and network meta-analyses. Health Technology
Assessment international (HTAi). 10th - 14th May 2016. Abstract.
Huxley N, Snowsill T, Hoyle M, Crathorne L, Haasova M, Briscoe S, Coelho H, Medina-Lara A, Mujica-Mota R, Napier M, et al (2014). A COST-EFFECTIVENESS ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATING CANCER-TREATMENT INDUCED ANAEMIA.  Author URL.
Hoyle M (2014). KEY DRIVERS OF COST-EFFECTIVENESS OF ANTI-CANCER DRUGS.  Author URL.
Snowsill T, Huxley N, Hoyle M, Crathorne L, Haasova M, Briscoe S, Coelho H, Medina-Lara A, Mota MR, Napier M, et al (2014). MODEL-BASED COST-UTILITY ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR THE TREATMENT OF CANCER-TREATMENT INDUCED ANAEMIA IN THE UK NHS.  Author URL.
Huxley N, Snowsill T, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C (2013). COST-EFFECTIVENESS OF SYSTEMATIC TESTING FOR LYNCH SYNDROME IN PATIENTS NEWLY DIAGNOSED WITH COLORECTAL CANCER IN THE UNITED KINGDOM.  Author URL.
Joulain F, Iqbal S, Diamand F, Van Cutsem E, Hoyle M, Allegra C (2012). AFLIBERCEPT VERSUS PLACEBO IN COMBINATION WITH FOLFIRI IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER: MEAN OVERALL SURVIVAL FOR SUBGROUPS FROM VELOUR.  Author URL.
Joulain F, Van Cutsem E, Iqbal SU, Hoyle M, Allegra CJ (2012). Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): Mean overall survival (OS) estimation from a phase III trial (VELOUR).  Author URL.
Hoyle M, Pavey T, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, et al (2012). GENERAL METHODOLOGICAL ISSUES IN COST-EFFECTIVENESS ANALYSIS INSPIRED BY THE ASSESSMENT OF DASATINIB, NILOTINIB AND IMATINIB FOR 1ST-LINE CHRONIC MYELOID LEUKAEMIA.  Author URL.
Peters JL, Hoyle M, Anderson R (2010). STRUCTURAL UNCERTAINTY IN COST-EFFECTIVENESS MODELS OF TREATMENT FOR ALZHEIMER'S DISEASE.  Author URL.
Hoyle M, Anderson R (2008). PREVALENT AND MULTIPLE FUTURE INCIDENT COHORTS IN COST-EFFECTIVENESS ANALYSIS.  Author URL.

Reports

Mujica-mota R, Varley-Campbell J, Tikhonova I, Cooper C, Hoyle MW, Rudin C, Rule S, Snowsill T (2016). Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: a Single Technology Appraisal. Author URL.  Full text.
Varley-Campbell J, Mujica-Mota R, Tikhonova I, Cooper C, Griffin E, Haasova M, Peters J, Lucherini S, Talens-Bou J, Long L, et al (2016). Everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression.
Huxley N, Long L, Briscoe S, Hoyle MW (2016). The clinical and cost-effectiveness of lenalidomide for people who have received at least one prior therapy with bortezomib (partial review of TA171): a critique of the submission from Celgene: Addendum.
Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M, Hoyle MW, et al (2015). Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer. MTA for NICE. Author URL.
Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, et al (2015). Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85). MTA for NICE. Author URL.
Hoyle MW, Long L, Huxley, N, Crathorne L, Briscoe S, Rudin C (2014). Obinutuzumab in combination with chlorambucil for previously untreated chronic lymphocytic leukaemia: a critique of the submission from Roche. NICE STA.  Author URL.
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long L, Medina-Lara A, et al (2014). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142). Author URL.
Hoyle M, Snowsill T, Haasova M, Cooper C, Rudin C (2013). Bosutinib for previously treated chronic myeloid leukaemia: a Single Technology Appraisal. Critique of submission from Pfizer. Submitted to NICE.  Author URL.
Hoyle M, Pavey T, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, et al (2011). Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Submitted to NICE as MTA report.  Author URL.
Hoyle MW, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Hyde C (2011). The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model. Submitted to NICE as MTA report.  Author URL.
Hoyle MW, Crathorne L, Jones-Hughes T, Stein K (2010). Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate: a critique of the submission from Napp. Submitted to NICE as STA report.  Author URL.
Hoyle M, Crathorne L, Moxham T, Garside R, Hyde C (2010). Ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Submitted to NICE as STA report.  Author URL.
Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Jeffreys M, et al (2010). The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of mild to moderate Alzheimer’s disease (review of TA111): a systematic review and economic model. Submitted to NICE as MTA report.  Author URL.
Thompson-Coon J, Hoyle M, Pitt M, Rogers G, Moxham T, Liu Z, Stein K (2009). Dasatinib and Nilotinib for imatinib-resistant or intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Submitted to NICE as MTA report.  Author URL.
Bond M, Hoyle M, Moxham T, Napier M, Anderson R (2009). Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer. Submitted to NICE as STA report.  Author URL.
Thompson-Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K (2008). Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Submitted to NICE as MTA report.  Author URL.
Hoyle MW, Rogers G, Garside R, Moxham T, Stein K (2008). The clinical- and cost effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene. Submitted to NICE as STA report.  Author URL.
Bond M, Pitt M, Akoh J, Moxham T, Hoyle M, Anderson R (2008). The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model. NIHR HTA, NICE.
Garside R, Green C, Hoyle M, Taylor R, Price A, Stein K (2007). The effectiveness and cost effectiveness of natalizumab for multiple sclerosis: an evidence review of the submission from Biogen. Submitted to NICE as STA report.  Author URL.
Bond M, Mealing S, Anderson R, Elston J, Weiner G, Taylor R, Hoyle M, Liu Z, Price A, Stein K, et al (2007). The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. Submitted to NICE as MTA report.  Author URL.

Publications by year


In Press

Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long H, Medina-Lara A, et al (In Press). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model. Health Technology Assessment Abstract.  Full text.

2017

Tikhonova IA, Hoyle MW, Snowsill TM, Cooper C, Varley-Campbell JL, Rudin CE, Mujica Mota RE (2017). Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: an Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. Pharmacoeconomics, 35(3), 363-373. Abstract.  Author URL.

2016

Tikhonova IA, Hoyle M, Snowsill T, Cooper C, Varley-Campbell J, Rudin C, Mujica Mota R (2016). Azacitidine for Treating Acute Myeloid Leukaemia: a Nice Single Technology Appraisal. ISPOR.
Mujica-mota R, Varley-Campbell J, Tikhonova I, Cooper C, Hoyle MW, Rudin C, Rule S, Snowsill T (2016). Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: a Single Technology Appraisal. Author URL.  Full text.
Tikhonova IA, Hoyle M, Snowsill T, Crathorne L, Varley-Campbell J, Peters J, Briscoe S, Bond M, Huxley N (2016). Cost Effectiveness of Cetuximab and Panitumumab for First-Line RAS WT Metastatic Colorecal Cancer. ISPOR.
Varley-Campbell J, Mujica-Mota R, Tikhonova I, Cooper C, Griffin E, Haasova M, Peters J, Lucherini S, Talens-Bou J, Long L, et al (2016). Everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression.
Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, et al (2016). Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess, 20(62), 1-594. Abstract.  Author URL.  Full text.
Haasova M, Jones-Hughes T, Peters J, Snowsill T, Coelho H, Crathorne L, Mujica Mota R, Varley-Campbell J, Huxley N, Moore J, et al (2016). Immunosuppressive therapy for renal transplantation in adults: a systematic review and network meta-analyses. Health Technology
Assessment international (HTAi). 10th - 14th May 2016. Abstract.
Huxley N, Long L, Briscoe S, Hoyle MW (2016). The clinical and cost-effectiveness of lenalidomide for people who have received at least one prior therapy with bortezomib (partial review of TA171): a critique of the submission from Celgene: Addendum.

2015

Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C (2015). A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC Cancer, 15 Abstract.  Author URL.  Full text.
Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M, Hoyle MW, et al (2015). Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer. MTA for NICE. Author URL.
Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, et al (2015). Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85). MTA for NICE. Author URL.

2014

Huxley N, Snowsill T, Hoyle M, Crathorne L, Haasova M, Briscoe S, Coelho H, Medina-Lara A, Mujica-Mota R, Napier M, et al (2014). A COST-EFFECTIVENESS ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATING CANCER-TREATMENT INDUCED ANAEMIA.  Author URL.
Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C (2014). A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technology Assessment, 18(58). Author URL.  Full text.
Hoyle M (2014). KEY DRIVERS OF COST-EFFECTIVENESS OF ANTI-CANCER DRUGS.  Author URL.
Snowsill T, Huxley N, Hoyle M, Crathorne L, Haasova M, Briscoe S, Coelho H, Medina-Lara A, Mota MR, Napier M, et al (2014). MODEL-BASED COST-UTILITY ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR THE TREATMENT OF CANCER-TREATMENT INDUCED ANAEMIA IN THE UK NHS.  Author URL.
Hoyle MW, Long L, Huxley, N, Crathorne L, Briscoe S, Rudin C (2014). Obinutuzumab in combination with chlorambucil for previously untreated chronic lymphocytic leukaemia: a critique of the submission from Roche. NICE STA.  Author URL.
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long L, Medina-Lara A, et al (2014). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142). Author URL.
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long L, Medina-Lara A, et al (2014). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model.  Author URL.

2013

Hoyle M, Snowsill T, Haasova M, Cooper C, Rudin C (2013). Bosutinib for previously treated chronic myeloid leukaemia: a Single Technology Appraisal. Critique of submission from Pfizer. Submitted to NICE.  Author URL.
Huxley N, Snowsill T, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C (2013). COST-EFFECTIVENESS OF SYSTEMATIC TESTING FOR LYNCH SYNDROME IN PATIENTS NEWLY DIAGNOSED WITH COLORECTAL CANCER IN THE UNITED KINGDOM.  Author URL.
Ciani O, Hoyle M, Pavey T, Cooper C, Garside R, Rudin C, Taylor R (2013). Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case-study for technology appraisal on the basis of surrogate outcomes evidence. Value in Health, 6(16), 1081-1090.
Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C (2013). Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer. Value Health, 16(2), 288-296. Abstract.  Author URL.
Peters JL, Anderson R, Hoyle M, Hyde C (2013). Evolution of a cost-utility model of donepezil for Alzheimer's disease. Int J Technol Assess Health Care, 29(2), 147-154. Abstract.  Author URL.
Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P, Moxham T, et al (2013). Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. Age Ageing, 42(1), 14-20. Abstract.  Author URL.
Joulain F, Proskorovsky I, Allegra C, Tabernero J, Hoyle M, Iqbal SU, Van Cutsem E (2013). Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. British Journal of Cancer, 109(7), 1735-1743. Author URL.
Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Tappenden P, Hyde C (2013). The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol Assess, 17(14), 1-237. Abstract.  Author URL.  Full text.

2012

Joulain F, Iqbal S, Diamand F, Van Cutsem E, Hoyle M, Allegra C (2012). AFLIBERCEPT VERSUS PLACEBO IN COMBINATION WITH FOLFIRI IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER: MEAN OVERALL SURVIVAL FOR SUBGROUPS FROM VELOUR.  Author URL.
Joulain F, Van Cutsem E, Iqbal SU, Hoyle M, Allegra CJ (2012). Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): Mean overall survival (OS) estimation from a phase III trial (VELOUR).  Author URL.
Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K (2012). Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess, 16(22), 1-410. Abstract.  Author URL.  Full text.
Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, et al (2012). Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: Systematic reviews and economic analyses. Health Technology Assessment, 16, 1-278. Abstract.  Author URL.
Hoyle M, Pavey T, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, et al (2012). GENERAL METHODOLOGICAL ISSUES IN COST-EFFECTIVENESS ANALYSIS INSPIRED BY THE ASSESSMENT OF DASATINIB, NILOTINIB AND IMATINIB FOR 1ST-LINE CHRONIC MYELOID LEUKAEMIA.  Author URL.
Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, et al (2012). The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess, 16(21), 1-470. Abstract.  Author URL.  Full text.

2011

Hoyle M (2011). Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis. Pharmacoeconomics, 29(1), 1-15. Abstract.  Author URL.
Hoyle M, Rogers G, Moxham T, Liu Z, Stein K (2011). Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health, 14(8), 1057-1067. Abstract.  Author URL.
Hoyle M, Pavey T, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, et al (2011). Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Submitted to NICE as MTA report.  Author URL.
Hoyle MW (2011). GENERAL METHODOLOGICAL ISSUES IN COST-EFFECTIVENESS ANALYSIS INSPIRED BY THE ASSESSMENT OF DASATINIB, NILOTINIB AND IMATINIB FOR CHRONIC MYELOID LEUKAEMIA. VALUE IN HEALTH, 14(7), A425-A425. Author URL.
Hoyle MW, Henley W (2011). Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol, 11. For Spreadsheet to implement method, click on Author URL Abstract.  Author URL.  Full text.
Hoyle M, Crathorne L, Garside R, Hyde C (2011). Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Health Technol Assess, 15 Suppl 1, 61-67. Abstract.  Author URL.
Hoyle MW, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Hyde C (2011). The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model. Submitted to NICE as MTA report.  Author URL.

2010

Hoyle MW, Crathorne L, Jones-Hughes T, Stein K (2010). Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate: a critique of the submission from Napp. Submitted to NICE as STA report.  Author URL.
Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K (2010). Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess, 14(2), 1-iv. Abstract.  Author URL.  Full text.
Hoyle M, Green C, Thompson-Coon J, Liu Z, Welch K, Moxham T, Stein K (2010). Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. Value Health, 13(1), 55-60. Abstract.  Author URL.
Hoyle M, Green C, Thompson-Coon J, Liu Z, Welch K, Moxham T, Stein K (2010). Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma. Value Health, 13(1), 61-68. Abstract.  Author URL.
Hoyle M (2010). Historical lifetimes of drugs in England: application to value of information and cost-effectiveness analyses. Value Health, 13(8), 885-892. Abstract.  Author URL.
Hoyle MW (2010). IMPROVED SURVIVAL CURVE FITS TO SUMMARY DATA FOR ECONOMIC EVALUATIONS. VALUE IN HEALTH, 13(7), A339-A339. Author URL.
Hoyle M, Crathorne L, Moxham T, Garside R, Hyde C (2010). Ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Submitted to NICE as STA report.  Author URL.
Coon JST, Liu Z, Hoyle M, Rogers G, Green C, Moxham T, Welch K, Stein K (2010). Reply: SUN vs BEV\+IFN in first-line mRCC therapy: No evidence for a statistically significant difference in progression-free survival. British Journal of Cancer, 102(1), 234-235. Full text.
Peters JL, Hoyle M, Anderson R (2010). STRUCTURAL UNCERTAINTY IN COST-EFFECTIVENESS MODELS OF TREATMENT FOR ALZHEIMER'S DISEASE.  Author URL.
Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Jeffreys M, et al (2010). The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of mild to moderate Alzheimer’s disease (review of TA111): a systematic review and economic model. Submitted to NICE as MTA report.  Author URL.
Hoyle M, Anderson R (2010). Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts. Med Decis Making, 30(4), 426-437. Abstract.  Author URL.  Full text.

2009

Hoyle M (2009). ACCOUNTING FOR THE DRUG LIFE CYCLE AND FUTURE DRUG PRICES IN COST EFFECTIVENESS ANALYSIS. VALUE IN HEALTH, 12(7), A233-A233. Author URL.
Thompson-Coon J, Hoyle M, Pitt M, Rogers G, Moxham T, Liu Z, Stein K (2009). Dasatinib and Nilotinib for imatinib-resistant or intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Submitted to NICE as MTA report.  Author URL.
Hoyle M, Cresswell JE (2009). Maximum feasible distance of windborne cross-pollination in Brassica napus: a 'mass budget' model. Ecological Modelling, 220(8), 1090-1097. Abstract.
Thompson Coon JS, Liu Z, Hoyle M, Rogers G, Green C, Moxham T, Welch K, Stein K (2009). Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer, 101(2), 238-243. Abstract.  Author URL.  Full text.
Bond M, Hoyle M, Moxham T, Napier M, Anderson R (2009). Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer. Submitted to NICE as STA report.  Author URL.
Bond M, Hoyle M, Moxham T, Napier M, Anderson R (2009). Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer. Health Technol Assess, 13 Suppl 2, 69-74. Abstract.  Author URL.
Bond M, Mealing S, Anderson R, Elston J, Weiner G, Taylor RS, Hoyle M, Liu Z, Price A, Stein K, et al (2009). The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. Health Technol Assess, 13(44), 1-330. Abstract.  Author URL.  Full text.
Bond M, Pitt M, Akoh J, Moxham T, Hoyle M, Anderson R (2009). The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model. Health Technology Assessment, 13(38), xi-180. Author URL.

2008

Thompson-Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K (2008). Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Submitted to NICE as MTA report.  Author URL.
Hoyle M (2008). Future drug prices and cost-effectiveness analyses. Pharmacoeconomics, 26(7), 589-602. Abstract.  Author URL.
Hoyle M, Anderson R (2008). PREVALENT AND MULTIPLE FUTURE INCIDENT COHORTS IN COST-EFFECTIVENESS ANALYSIS.  Author URL.
Hoyle MW, Rogers G, Garside R, Moxham T, Stein K (2008). The clinical- and cost effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene. Submitted to NICE as STA report.  Author URL.
Bond M, Pitt M, Akoh J, Moxham T, Hoyle M, Anderson R (2008). The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model. NIHR HTA, NICE.

2007

Hoyle M, Cresswell JE (2007). A search theory model of patch-to-patch forager movement with application to pollinator-mediated gene flow. J Theor Biol, 248(1), 154-163. Abstract.  Author URL.
Hoyle M, Hayter K, Cresswell JE (2007). Effect of pollinator abundance on self-fertilization and gene flow: application to GM Canola. Ecol Appl, 17(7), 2123-2135. Abstract.  Author URL.
Cresswell JE, Hoyle M (2007). The effect of wind direction on cross-pollination in wind-pollinated GM crops. Ecological Applications, 17(4), 1234-1243.
Garside R, Green C, Hoyle M, Taylor R, Price A, Stein K (2007). The effectiveness and cost effectiveness of natalizumab for multiple sclerosis: an evidence review of the submission from Biogen. Submitted to NICE as STA report.  Author URL.
Bond M, Mealing S, Anderson R, Elston J, Weiner G, Taylor R, Hoyle M, Liu Z, Price A, Stein K, et al (2007). The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. Submitted to NICE as MTA report.  Author URL.
Hoyle M (2007). When corridors work: Insights from a microecosystem. ECOLOGICAL MODELLING, 202(3-4), 441-453. Author URL.

2006

Cresswell JE, Hoyle, M. (2006). A mathematical method for estimating patterns of flower-to-flower gene dispersal from a simple field experiment. Functional Ecology, 20, 245-251.
Cresswell, J.E. (2006). Remobilization of initially deposited pollen grains has negligible impact on gene dispersal in bumble bee-pollinated Brassica napus. Functional Ecology, 20, 958-965.

2005

Hoyle M (2005). Experimentally fragmented communities are more aggregated. Journal of Animal Ecology, 74(3), 430-442. Abstract.
Hoyle M, James M (2005). Global warming, human population pressure, and viability of the world's smallest butterfly. Conservation Biology, 19(4), 1113-1124. Abstract.
Hoyle M, Harborne AR (2005). Mixed effects of habitat fragmentation on species richness and community structure in a microarthropod microecosystem. Ecological Entomology, 30(6), 684-691. Abstract.

2004

Hoyle M (2004). Causes of the species-area relationship by trophic level in a field-based microecosystem. Proc Biol Sci, 271(1544), 1159-1164. Abstract.  Author URL.
Jackson J, Turner J, Rentoul L, Faulkner H, Behnke J, Hoyle M, Grencis R, Else K, Kamgno J, Bradley J, et al (2004). Cytokine response profiles predict species-specific infection patterns in human GI nematodes. International Journal for Parasitology, 34, 1237-1244.
Hoyle MW, Gilbert F (2004). Species richness of moss landscapes unaffected by short-term fragmentation. Oikos, 105, 359-367.
Jackson J, Turner J, Rentoul L, Faulkner H, Behnke J, Hoyle M, Grencis R, Else K, Kamgno J, Boussinesq M, et al (2004). T Helper Cell Type 2 responsiveness predicts future susceptibility to gastrointestinal nematodes in humans. Journal of Infectious Diseases, 190, 1804-1811.

Awards

2011 ISPOR International Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research

One of two runners-up for the University of Plymouth Early Career Researcher of 2011.


Advice to Government, Parliament, devolved and English regional administrations, other national, international, regional or local agencies; advice to non-government organisations and to private practice

Working Party member on implemention of NICE Fast Track Appraisal (FTA) process

Advisor to NICE on implementation of the "Adjusted TA" process.


Committee/panel activities

Panel member for the Research for Patient Benefit (RfPB) South West.
 


External Examiner Positions

External examiner for the MSc in Health Economics and Decision Modelling, University of Sheffield


Invited lectures & workshops

Invited speaker on methods to recreate individual patient data at InterTASC (association of UK TAR groups) meeting on survival analysis, York, 13th Oct 2014

Invited speaker and panel member at the Office of Health Economics workshop “Methodological Advances for Modelling Cost-effectiveness of Cancer Medicines”, London, 23rd April 2012.

Invited speaker at MRC workshop “Adjusting for Treatment Switching in RCTs”, February 20th 2012.

Invited oral presentation on new NICE Fast Track Assessment process to NICE and TAR centres, London, 29th Sept 2017.


Invited lectures

Invited Oral presentation at 3rd Annual Oncology Market & Patient Access conference in Barcelona, February 15th-16th 2011.

Invited speaker and panel member at the Office for Health Economics Pharmaceutical Industry Health Economics Group (PIHEG) 26th November 2008 on his paper “Future drugs prices and cost-effectiveness analyses”.


Media Coverage

Project team's work on health technology assessments for NICE regularly appears in the national news, e.g. BBC News: drugs for Alzheimer’s disease

Currently helping to develop a new module on HTA for BSc Health Research Pathway in Medical Sciences at University of Exeter.

Occasional teaching in University of Exeter Medical School;

  • Statistics to medical students and postgraduates.
  • Systematic reviews, statistics and diagnostic testing to medical students.
  • Health economics to medical students.

Back | Edit Profile